MigluSTAT hydrochloride 是一种葡萄糖神经酰胺合酶抑制剂，可用于 I 型戈谢病的相关研究。

Miglustat hydrochloride is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease.

Consumption of a standard high-fat breakfast within 30 minutes before administration of Miglustat hydrochloride significantly reduced peak exposure but did not significantly affect the extent of systemic exposure to Miglustat hydrochloride. The Cmax decreased by 36% on average following administration with food. AUC showed a modest (14%) decrease with food, but the 90% confidence interval was within the acceptance limit of 80% to 125%. Tmax was prolonged from 2.5 (1.0-4.0) hours in the fasted state to 4.5 (1.5-8.0) hours in the fed state, whereas the apparent terminal half-life was approximately 8 hours and not affected by food[1].

210110-90-0

C10H22ClNO4

255.74

盐酸美格鲁特;NB-DNJ hydrochloride;OGT918 hydrochloride;N-Butyldeoxynojirimycin hydrochloride

H2O:32 mg/mL (125.13 mM)
DMSO:60 mg/mL (234.61 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years